Skip to main content

Limited Advantage to Very Early vs. Delayed Etanercept in RA

The VEDERA study sought to confirm whether the very early introduction of first-line etanercept+methotrexate (ETN+MTX) was superior to treat-to-target MTX (MTX-TT) in patients with early RA.

The study enrolled 120  treatment-naïve seropositive ERA (≤12 months symptom) patients with active disease (DAS28-ESR ≥3.2) and studied by clinical measures or ultrasound power Doppler (PD). Subjects receiving MTX-TT, were escalated to ETN if week 24 DAS28-ESR ≥2.6. The primary endpoint DAS28ESR remission was assessed at week 48.

The group was 71% female, 73% RF/84% ACPA positive, with a median symptom duration 20.3 and basedline DAS28 of 5.1 (1.1)).

Remission rates were:

Week 24                 Week 48

  • ETN+MTX= 38%                     52%
  • MTX-TT  = 33%                      38%    (ORs 1.6, 95% CI 0.8 to 3.5, p=0.211).

Sustained DAS28-ESR remission more likely with ETN+MTX versus MTX-TT (42% and 27%; p=0.035).

If ETN administered first line, there was an almost 3-fold increase odds (OR 2.84) of achieving remission, compared to starting ETN after 24 weeks of just MTX therapy.

While previous studies suggested that very early introduction of TNFI+MTX would have a larger beneficial effect, these studies failed to prove this contention, although giving ETN after failure of MTX-TT did yield lesser responses.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject